Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size

被引:28
作者
Foulon, T
Payen, N
Laporte, F
Bijaoui, S
Dupont, G
Roland, F
Groslambert, P
机构
[1] CHU Grenoble, Dept Biol Integree, Grenoble 09, France
[2] Serv Med Prevent Interuniv Grenoble, F-38400 St Martin Dheres, France
关键词
oral contraceptives; desogestrel; levonorgestrel; serum lipids; HDL subclasses; LDL size;
D O I
10.1016/S0010-7824(01)00224-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This study was designed to determine the effects of two low-dose oral contraceptives, most frequently given in our area, monophasic desogestrel/ethinylestradiol (DG/EE) and triphasic levonorgestrel/ethinylestradiol (LNG/EE), on lipoprotein parameters, especially LDL particle size and HDL subclass distribution (determined by lipid-stained 2%-20% polyacrylamide gradient gel electrophoresis) in 37 healthy normolipidemic women aged 19 to 27 years. Lipid and lipoprotein parameters were measured before the start of treatment and in the third month of oral contraceptive use. Results reflected the estrogen-progestin balance. As compared with baseline values, with both formulations, plasma total cholesterol, phospholipids, and HDL3 cholesterol increased, and LDL-predominant peak size decreased, with a translation of LDL pattern A towards pattern I. With DG/EE, plasma triglycerides, apolipoproteins AI and B increased. With LNG/EE, LDL cholesterol increased, and HDL2 cholesterol decreased. All these modifications were moderate, within threshold limits. Estrogen-dominant monophasic DG/EE appears to be more favorable than progestin-dominant triphasic LNG/EE, since the reduction in LDL-predominant peak size is not associated with an increase in LDL cholesterol or with a decrease in HDL2 cholesterol. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:11 / 16
页数:6
相关论文
共 37 条
[31]  
Silva ERDE, 1999, J LIPID RES, V40, P1211
[32]   PAST USE OF ORAL-CONTRACEPTIVES AND CARDIOVASCULAR-DISEASE - A METAANALYSIS IN THE CONTEXT OF THE NURSES HEALTH STUDY [J].
STAMPFER, MJ ;
WILLETT, WC ;
COLDITZ, GA ;
SPEIZER, FE ;
HENNEKENS, CH .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (01) :285-291
[33]   CHANGES IN THE LOW-DENSITY-LIPOPROTEIN PROFILE DURING 17-BETA-ESTRADIOL DYDROGESTERONE THERAPY IN POSTMENOPAUSAL WOMEN [J].
VANDERMOOREN, MJ ;
DEGRAAF, J ;
DEMACKER, PNM ;
DEHAAN, AFJ ;
ROLLAND, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1994, 43 (07) :799-802
[34]   Lipid transfer reactions and lipid composition of low-density lipoprotein particles in postmenopausal women receiving estrogen [J].
Wakatsuki, A ;
Ikenoue, N ;
Okatani, Y .
OBSTETRICS AND GYNECOLOGY, 1999, 94 (04) :492-497
[35]   EFFECTS OF LOW-DOSE ORAL-CONTRACEPTIVES ON VERY LOW-DENSITY AND LOW-DENSITY-LIPOPROTEIN METABOLISM [J].
WALSH, BW ;
SACKS, FM .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (05) :2126-2132
[36]   Estradiol 17β inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees [J].
Zhu, XD ;
Bonet, B ;
Knopp, RH .
ATHEROSCLEROSIS, 2000, 148 (01) :31-41
[37]   Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: Implications for atherogenesis [J].
Zhu, XD ;
Bonet, B ;
Gillenwater, H ;
Knopp, RH .
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 222 (03) :214-221